TH135822B - Methods and constituents for inhibition of Treg cells (Treg CELLS) - Google Patents
Methods and constituents for inhibition of Treg cells (Treg CELLS)Info
- Publication number
- TH135822B TH135822B TH1201005448A TH1201005448A TH135822B TH 135822 B TH135822 B TH 135822B TH 1201005448 A TH1201005448 A TH 1201005448A TH 1201005448 A TH1201005448 A TH 1201005448A TH 135822 B TH135822 B TH 135822B
- Authority
- TH
- Thailand
- Prior art keywords
- cells
- treg cells
- treg
- constituents
- methods
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract 9
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 239000000470 constituent Substances 0.000 title abstract 2
- 230000001225 therapeutic Effects 0.000 claims abstract 4
- 230000000735 allogeneic Effects 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 230000001077 hypotensive Effects 0.000 claims abstract 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 101700082799 IL2RA Proteins 0.000 claims 1
- 102100002950 ISG20 Human genes 0.000 claims 1
- 101700015336 ISG20 Proteins 0.000 claims 1
- 210000000447 Th1 Cells Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 210000002602 induced regulatory T cell Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000038129 antigens Human genes 0.000 abstract 5
- 108091007172 antigens Proteins 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 210000004027 cells Anatomy 0.000 abstract 3
- 239000006166 lysate Substances 0.000 abstract 2
- 210000003162 effector T lymphocyte Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Abstract
การประดิษฐ์ครั้งนี้เกี่ยวข้องกับวิธีการของการกดการดื้อต่อภูมิคุ้มกันของโรคหรือ แอนติเจนของโรคในผู้ป่วย อีกทั้งวิธีการจะส่งเสริมฤทธิ์ของเอฟเฟคเตอร์ T ลิมโฟไซต์ (effector T lymphocytes) การประดิษฐ์จะรวมถึงการให้องค์ประกอบเชิงการบำบัดรักษาที่ส่งเสริมสิ่งแวดล้อม Th1 ในผู้ป่วยในขณะที่ทำการลดฤทธิ์เชิงการกดภูมิคุ้มกันของ Treg เซลล์ (Treg cells) ที่จะสามารถ นำไปสู่การดื้อของแอนติเจนของโรค และการเลี้ยงภูมิคุ้มกันของแอนติเจนของโรคโดยผู้ป่วย องค์ประกอบเชิงการบำบัดรักษาจะรวมถึงอัลโลเจนอิก emTh-1 เซลล์ (allogeneic emTh-1 cells) อีกทั้งองค์ประกอบเชิงการบำบัดรักษาจะรวมถึงแอนติเจนของโรค เช่น เซลล์ไลเซทที่อุดมด้วย แชพเพอโรน (chaperone-rich cell lysate) ของแอนติเจนของโรค This invention relates to methods of suppressing immune resistance or Disease antigens in the patient In addition, the method will promote the effect of the effector T lymphocytes, the invention will include the administration of a therapeutic component that promotes the Th1 environment in the patient while reducing the hypotensive effect. Immunity of Treg cells (Treg cells) that can lead to antigens resistance. And immunization of disease antigens by patients. Therapeutic elements include allogeneic emTh-1 cells, as well as therapeutic constituents, such as disease antigens such as chapperro-rich lysate cells. (Chaperone-rich cell lysate) of disease antigens
Claims (3)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH135822B true TH135822B (en) | 2014-08-07 |
| TH135822A TH135822A (en) | 2014-08-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012149282A3 (en) | Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells | |
| EP4324479A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| MX2013004817A (en) | Inflammatory disease. | |
| NZ628328A (en) | Rna formulation for immunotherapy | |
| MX358099B (en) | Human immunodeficiency virus neutralizing antibodies adn methods of use thereof. | |
| CO6690760A2 (en) | Non-lipidated variants of neisseria meningitidis orf2086 antigens | |
| EP2702994A3 (en) | Methods of administering pirfenidone therapy | |
| WO2012054509A3 (en) | Discovery of regulatory t cells programmed to suppress an immune response | |
| MX347734B (en) | S100a4 antibodies and therapeutic uses thereof. | |
| EA202090699A3 (en) | COMPOSITIONS CONTAINING A BUFFER, VACCINES THAT CONTAIN COMPOSITIONS CONTAINING A BUFFER, AND THEIR APPLICATION | |
| WO2014205199A3 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
| WO2011130249A3 (en) | Methods and compositions for inhibition of treg cells | |
| WO2012047267A3 (en) | Polyvalent immunogen | |
| MX2017013564A (en) | Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration. | |
| SG10201901391RA (en) | Induction of il-12 using immunotherapy | |
| PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| JP2016531853A5 (en) | ||
| JP2013523886A5 (en) | ||
| MX2015017257A (en) | Compositions and methods of immunizing against c. difficile. | |
| WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy | |
| TH135822B (en) | Methods and constituents for inhibition of Treg cells (Treg CELLS) | |
| WO2013173256A3 (en) | New and improved influenza vaccines | |
| TH135822A (en) | Methods and constituents for inhibition of Treg cells (Treg CELLS) | |
| IN2014DN10408A (en) |